



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61645

Title: Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96-week

Reviewer's code: 02943023

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2020-12-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-17 09:15

Reviewer performed review: 2020-12-28 08:27

Review time: 10 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This manuscript is well organized and appropriately presented. I think that the results of this study has valuable contributions to treatment of chronic hepatitis B patients with Qingzhong, a brand name of TDF, commercialized in China. I have a couple of minor comments. 1. In the title of manuscript, i.e. 'Tenofovir disoproxil fumarate (Qingzhong versus Viread) in patients with chronic hepatitis B: Results of a multicenter, double-blind, double-dummy, clinical trial at week 96', it seems suggesting that this study compared the efficacy of Qingzhong versus Viread in CHB patients at week 96. However, all patients received treatment with Qingzhong 300 mg once daily from week 49 to week 96. 2. Many previous studies pointed out safety issues about kidney function and bone density. However, in this study, the adverse events in relation to kidney impairment and reductions of bone density were very uncommon. Did you have data about change in renal function (i.e. eGFR) or bone density in the study population? What your opinion or explanation for that? 3. In Table 1, the title was describe as '..... HBeAg-positive entecavir long-term cohort'. Please check that again.